Notizia - Recent Pharma, Healthcare and Biotech Happenings

Myovant Pfizer Deal_Generic for Severe Hypoglycemia_Teleflex

A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica

A USD 4.2 Billion Myovant/ Pfizer Deal Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health. Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist. If approved, it will be marketed under the brand name Orgovyx for prostate cancer as well as in women’s health in combination with estradiol 1.0 mg and norethindrone acetate (0.5 mg) in the US and Canada. However, for geographies other than the US and Canada, Pfizer has received an exclusive right to develop the drug ...

Explore More...

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Insights

Notizia - Recent Pharma, Healthcare and Biotech Happenings

A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica

FDA accepts; Keytruda takes lead; M Pharmaceutical develops; Merck Deploys Palantir

Aurobindo takes top generic spot; Valeant unloads Dendreon; Ipsen strikes $1B deal; Takeda shells out $5.2B

Sanofi, Regeneron one step closer; Pharma’s deal; J&J and Actelion deal

Sanofi sues Novo; Allergan gets help; Actelion snubs; Impax CEO Wilkinson out

Pfizer uses; FDA approves; EMA approves; Mylan launches

CDC study reveals; Jevtana receives yes; Herantis secures; Immuno-oncology is not cost-effective

Novartis joins; Sanofi weighs Actelion; Valeant and Takeda’s $10B deal; Astellas scouts pipeline

Glaxo replaces ViiV; Lilly nets; AstraZeneca shuffles off; Gazyva aims to beat

More Views & Analysis

EC grants; Pfizer cuts; 27 medicines sold; Keytruda nabs

Novartis Buys; FDA approves; Mayne Pharma Launches; Oxford Genetics Receives Grant

Novartis eyes; Pfizer considers cashing; Mylan pushes to seal $465M; Valeant with Takeda for deal

Aurobindo’s net profit; LLS selects; Eli Lilly secures; DNA vaccine against Zika

Collaborate for TYG Oncology; GE Healthcare and Valneva collaboration; UPS to Acquire Marken

Fresenius Kabi introduced Bivalirudin; Envigo Launches; Mylan’s MAA accepted; Pricing hit pharma

Sun Pharma Announces Launch; OptiNose files; Opiant obtains rights; Swissmedic approves

Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV

Subscribe to our Updates

Daily

Weekly

Monthly